Does EPA help produce pro-resolving mediators and counter arachidonic acid-derived inflammation signaling?

Eicosapentaenoic acid (EPA) plays a critical role in cell membranes by balancing inflammatory and resolving lipid mediators.

Biochemical pathways

• Precursor function: EPA is the obligate biological precursor for E-series resolvins (RvE1–RvE4), which are specialized pro-resolving mediators (SPMs) that actively terminate inflammation. The pathway begins when EPA is oxygenated by cytochrome P450 or aspirin-acetylated COX-2 to generate 18-hydroxy-EPA (18-HEPE). This intermediate is subsequently metabolized by 5-lipoxygenase (5-LOX) in leukocytes to yield active RvE1 and RvE2.
• Enzymatic competition: EPA directly competes with the omega-6 fatty acid arachidonic acid (AA) for membrane mobilization by phospholipase A2 (PLA2) and for downstream COX and LOX active sites. By acting as a competitive substrate and inhibitor, EPA increases the apparent Km of AA, suppressing the synthesis of highly inflammatory 2-series prostaglandins and 4-series leukotrienes.

Clinical and systemic implications

• Signaling shift: A low omega-3 status—clinically measured by a elevated AA/EPA ratio—leaves AA as the dominant enzymatic substrate. This deficiency shifts cellular signaling toward a highly active, pro-inflammatory pattern.
• Inflammatory biomarkers: High systemic AA/EPA ratios correlate with increased levels of circulating inflammatory markers, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and high-sensitivity C-reactive protein (hs-CRP). Supplementation with EPA helps restore this balance, limiting systemic inflammatory signaling and promoting the production of less-inflammatory 3-series prostaglandins and 5-series leukotrienes.

Bottom line

• Low EPA and omega-3 status shifts lipid signaling toward a pro-inflammatory state by reducing the biosynthesis of E-series resolvins and removing the competitive inhibition on arachidonic acid cascade pathways.